16 results about "HPV infection" patented technology

The present application relates to a kind of traditional Chinese medicine for treating female HPV infection, which is prepared from the following weight ratio of traditional Chinese medicine raw materials: 2-4 parts of catechu, 2-4 parts of half lotus, 2-4 parts of snakeberry, 1-2 parts of longjin, 1-2 parts of gotu kola, 1-2 parts of wintergreen, 1-2 parts of coptis, and 1-2 parts of sophora. The present application can effectively treat female HPV infection.

This invention discloses a composition and its preparation method for treating human papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN), belonging to the field of traditional Chinese medicine technology. The formula consists of 6-15 parts of American cockroach, 5-11 parts of hawthorn, 5-11 parts of chicory, 3-9 parts of *Scutellaria baicalensis*, 8-20 parts of *Sophora flavescens*, and 6-15 parts of *Cnidium monnieri*, and also contains 0.01-1 parts by weight of toad venom. The dosage form is one or more of the following: external gel, rinse, foam, suppository, and film preparation. It has high safety and is suitable for HPV infection and CIN changes, solving the problem of poor efficacy in existing treatments.

This invention discloses a dual-targeting DNA vaccine delivery system based on calcium phosphate lipid nanoparticles, belonging to the field of biomedicine. The delivery system comprises calcium phosphate containing histone H1 and an HPV E6 / E7 fusion gene plasmid, and a lipid bilayer membrane of DSPE-PEG-2000-Mannose. This system achieves targeted uptake by dendritic cells through mannose modification and relies on histone H1-mediated DNA nuclear transport. The dual targeting significantly enhances antigen expression efficiency. In vitro and in vivo experiments have demonstrated that this delivery system exhibits good biocompatibility and high stability, effectively activating antigen-specific T-cell immune responses, and possesses both HPV infection prevention and cervical cancer treatment effects, providing a new strategy for cervical cancer prevention and treatment.

The application discloses a traditional Chinese medicine composition and a traditional Chinese medicine preparation for treating HPV infection. Specifically, the traditional Chinese medicine composition comprises the following components: radix codonopsis 15-45 parts, rhizoma atractylodis macrocephalae 7-25 parts, radix astragali 20-60 parts, radix pseudostellariae 7-25 parts, radix ophiopogonis 7-25 parts, radix rehmanniae 10-30 parts, coriolus 15-45 parts, ganoderma 15-45 parts, smilax riparia 20-60 parts, oldenlandia 15-35 parts, herba taraxaci 15-35 parts, morus 20-40 parts, coix 15-35 parts, gardenia 7-25 parts, salvia miltiorrhiza 10-30 parts, portulaca 15-45 parts, poria 10-30 parts, isatis root 10-30 parts, dendrobium 7-25 parts, schisandra 7-25 parts, licorice 10-20 parts, and cyperus 15-35 parts.

This invention belongs to the field of biological detection technology, and particularly relates to a reproductive tract HPV-mRNA-E6 / E7 detection system and method based on nanopore sequencing. The system includes a sample pretreatment module, an RNA extraction and purification module, a reverse transcription module, a nanopore sequencing module, and a bioinformatics analysis module. The method includes the following steps: (1) reproductive tract sample collection and pretreatment; (2) extraction and purification of HPV-mRNA in the sample; (3) reverse transcription of the purified HPV-mRNA into cDNA; (4) nanopore sequencing of the cDNA to obtain raw sequencing data; (5) filtering, comparing, and annotating the sequencing data through the bioinformatics analysis module to achieve HPV type identification and quantitative analysis of E6 / E7 gene expression levels. This invention utilizes the advantages of nanopore sequencing, such as long read length and real-time detection, combined with the specificity of E6 / E7 mRNA as a biomarker of active infection. It can directly detect latent and active HPV infection, improve detection sensitivity, accurately distinguish infection types, and shorten the detection cycle. It enables rapid, accurate, and high-throughput detection of active HPV infection in the genital tract, providing reliable technical support for early screening, disease monitoring, and prognostic assessment of HPV-related diseases such as cervical cancer.

The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.

This invention relates to antisense oligonucleotides targeting different subtypes of human papillomavirus (HPV) oncogenes and their applications. The ASO molecules are 14–40 bases in length and specifically pair with specific regions of target genes. This invention also relates to the following applications of the ASO molecules: (1) preparing preparations to inhibit HPV virus expression; or (2) preparing drugs or drug compositions for treating diseases related to HPV infection; or (3) treating diseases related to HPV infection; or (4) inhibiting the expression of HPV virus genes.

This invention discloses a gynecological antibacterial hydrogel, its preparation method, and its application. The hydrogel comprises a water extract of traditional Chinese medicines including Verbena officinalis, Salvia miltiorrhiza, Portulaca oleracea, Sophora flavescens, Viola yedoensis, Phellodendron chinense, and Artemisia argyi, as well as lactic acid, chitosan, and water. The preparation involves a water extraction and alcohol precipitation purification process to obtain the herbal extract, which is then mixed with a chitosan-lactic acid swelling matrix, adjusted to pH 3.8-4.4, and then filled and sterilized. Based on the principles of traditional Chinese medicine (TCM) formulation and combined with modern pharmaceutical technology, this invention's gel possesses the effects of clearing heat and drying dampness, detoxifying and killing parasites, and promoting blood circulation and removing blood stasis. It exhibits strong inhibitory activity against common gynecological pathogens, restores the acidic environment of the vagina, regulates local immunity and microenvironment, has an adjunctive therapeutic effect on HPV infection, is non-irritating to the vaginal mucosa, and has high safety and good stability.

This invention discloses a strain of *Lactobacillus crispatus* push, classified as *Lactobacillus crispatus* push, deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35610, on August 13, 2025. The culture conditions were: 37°C, anaerobic, and 48 hours. This *Lactobacillus crispatus* strain exhibits significant advantages in inhibiting the growth of HPV-infected cervical epithelial cells and shows great potential in the treatment of HPV infection in the female lower genital tract.

This invention discloses the use of sulfonated chitosan in inhibiting human papillomavirus (HPV) infection. The sulfonated chitosan of this invention can inhibit HPV infection of cells in vitro and is non-toxic to cells, thus having the use in preventing or treating HPV infection and related diseases, especially cervical cancer and condyloma acuminata.

This invention discloses a traditional Chinese medicine composition for treating human papillomavirus (HPV) infection, its preparation method, and its application. The composition is made from multiple traditional Chinese medicines, including Polygonum cuspidatum, Polygonatum sibiricum, and Atractylodes macrocephala (fried), in a specific weight ratio. Through processes such as decoction extraction, concentration, and granulation, the composition can be prepared into various pharmaceutically acceptable dosage forms, including decoctions, granules, tablets, capsules, pills, powders, and oral liquids. The traditional Chinese medicine composition of this invention has the effects of "tonifying qi and kidneys, detoxifying and removing dampness, and supporting the body's resistance to pathogens," and can be effectively used to treat human papillomavirus (HPV) infection. The preparation process of this invention is simple, and the efficacy is definite, providing a new medication option for the clinical treatment of HPV infection.

This invention belongs to the field of biomedical technology, specifically disclosing a lyophilized powder capsule composed mainly of NKT cell-derived exosomes and its application. This invention is the first to systematically evaluate the safety and preliminary efficacy of NKT cell-derived exosomes as an immune remodeling intervention in individuals with persistent HPV infection. Furthermore, it combines NKT cell-derived exosomes with herbal ingredients such as Sophora flavescens, Cnidium monnieri, Bletilla striata, Arisaema heterophyllum, Bambusa textilis, Aquilaria sinensis, and vitamin B8 to prepare a lyophilized powder capsule composed mainly of NKT cell-derived exosomes. This capsule treats persistent HPV infection in women by enhancing the local specific immune response in the vagina, ultimately achieving HPV clearance and reducing the risk of cervical cancer. This invention has significant clinical application value and social significance.

This invention relates to a traditional Chinese medicine composition for treating chronic cervicitis complicated with HPV infection. The composition is made from the following raw materials in parts by weight: 26-34 parts raw Astragalus membranaceus, 26-34 parts Smilax glabra, 11-19 parts Toona sinensis root bark, and 26-34 parts raw Coix lacryma-jobi. This invention also provides the uses of the traditional Chinese medicine composition. In this invention, raw Astragalus membranaceus is the principal ingredient, tonifying Qi and strengthening the body's resistance; Smilax glabra and Toona sinensis root bark clear heat and dry dampness; and raw Coix lacryma-jobi dispels dampness and promotes tissue regeneration, serving as assistant ingredients; the entire formula works synergistically to strengthen the body's resistance, eliminate pathogenic factors, and promote tissue regeneration.

This application relates to the field of biomedical technology, specifically disclosing an immune-boosting preparation that promotes HPV viral genome methylation. The preparation comprises epigallocatechin gallate, folic acid, vitamin C, vitamin E, zinc gluconate, various B vitamins, and excipients. Its preparation method involves pretreatment of the raw materials and excipients, microencapsulation of some vitamins, staged mixing via gradient shearing, dry granulation, low-temperature vacuum staged drying, and granulation to produce an oral solid dosage form. This preparation can be used to intervene in HPV infection, achieving dual intervention by promoting HPV viral genome methylation and enhancing the body's immunity. It has the advantages of a rational formulation and stable active ingredients; its preparation process effectively avoids oxidative inactivation of active ingredients, ensuring the uniformity of the preparation, and is simple to operate, suitable for large-scale production, and can meet the needs of clinical and routine HPV infection intervention.

This invention discloses a recombinant β-lactoglobulin, its engineered Pichia pastoris strain, and anhydride modification method and applications, belonging to the field of biotechnology. This invention simultaneously knocks out the vacuolar protease PEP4 gene and the extracellular metalloproteinase YPS1 gene of Pichia pastoris, introduces an expression vector pPIC9K-BLG containing a codon-optimized β-lactoglobulin gene, and replaces the signal peptide with a secretion-enhancing signal peptide 0030 to obtain a recombinant plasmid. The recombinant plasmid is electroporated with competent Pichia pastoris cells, and then the folding system is transformed into a high-copy strain to obtain an engineered Pichia pastoris strain that secretes and expresses recombinant β-lactoglobulin, with the accession number CCTCC NO: M20251654. This invention also provides an anhydride modification method for the recombinant β-lactoglobulin, and the resulting modified protein has anti-HPV activity and can be used to prepare agents for the prevention and treatment of HPV infection.

This invention discloses a strain of *Lactobacillus gasseri*, classified as *Lactobacillus gasseri* push, deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35609, on August 13, 2025. The culture conditions were: 37°C, anaerobic, and 48 hours. This *Lactobacillus gasseri* strain exhibits significant advantages in inhibiting the growth of HPV-infected cervical epithelial cells and shows great potential in the treatment of HPV infections in the female lower genital tract.